Statistics for Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study
Total visits
| views | |
|---|---|
| Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study | 167 |
Total visits per month
| views | |
|---|---|
| May 2024 | 0 |
| June 2024 | 0 |
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
File Visits
| views | |
|---|---|
| nihms-1518357.pdf | 141 |
Top country views
| views | |
|---|---|
| United States | 110 |
| Germany | 4 |
| Ukraine | 3 |
| Canada | 2 |
| United Kingdom | 1 |
| Malaysia | 1 |
| Pakistan | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 47 |
| Fairfield | 12 |
| Houston | 12 |
| Cambridge | 9 |
| Jacksonville | 5 |
| Kiez | 4 |
| Ann Arbor | 3 |
| Kiev | 3 |
| Toronto | 2 |
| Washington | 2 |
| Chicago | 1 |
| Costa Mesa | 1 |
| Islamabad | 1 |
| Mountain View | 1 |
| San Francisco | 1 |
| Seremban | 1 |